$PBM News

Psyence BioMed Establishes Active Ibogaine Operations, Production Capabilities In Africa

Prestige Consumer Healthcare Announces agreement To Acquire LaCorium Health, A Leader In Australian Therapeutic Skin Care For ~150M

FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence Biomedical Announces First Patient Dosed In Phase Iib Clinical Trial Evaluating NPX-5 For Treatment Of Adjustment Disorder In Patients With Cancer In Palliative Care Setting

Psyence Biomedical Announces First Patient Dosed In Phase Iib Clinical Trial Evaluating NPX-5 For Treatment Of Adjustment Disorder In Patients With Cancer In Palliative Care Setting

Why Is Psyence Biomedical Stock Falling Wednesday?

Why Is Psyence Biomedical Stock Trading Lower On Tuesday?

Psyence Biomedical shares are trading higher after President Trump signed an executive order on accelerating medical treatments for serious mental illness.

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Psyence BioMed Builds Supply Pipeline For Psychedelic Drug Ibogaine As Demand Grows, Secures GMP-Grade Ibogaine Inventory To Support Research And Future Treatments

Top Midday Gainers

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence BioMed Acknowledges U.S. Executive Order Plans To Evaluate Ibogaine's Therapeutic Potential

Psyence Biomedical Shares Resume Trade

Psyence Biomedical Shares Halted On Circuit Breaker To The Upside, Stock Now Up 176.74%

Psyence Biomedical Shares Halted On Circuit Breaker To The Upside, Stock Now Up 76.39%

Psyence Biomedical Shares Resume Trade Following Circuit Breaker Halt